Novobiocin and related coumarins and depletion of heat shock protein 90- dependent signaling proteins

Journal of the National Cancer Institute

Volumn 92, Issue 3, 2000, Pages 242-248

  Marcu, Monica G ^a   Schulte, Theodore W ^a   Neckers, Leonard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOROBIOCIN; COUMAMYCIN A1; COUMARIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; NOVOBIOCIN; PROTEIN P53; RADICICOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBIOTIC THERAPY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; SEQUENCE HOMOLOGY;

EID: 0034594644     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.3.242     Document Type: Article

References (34)

1. Wilhelmsson A, Cuthill S, Denis M, Wikstrom AC, Gustafsson JA, Poellinger L. The specific DNA binding activity of the dioxin receptor is modulated by the 90 kd heat shock protein. EMBO J 1990;9:69-76.
2. Catelli MG, Binart N, Jung-Testas I, Renoir JM, Baulieu EE, Feramisco JR, et al. The common 90-kd protein component of non-transformed '8S' steroid receptors is a heat-shock protein. EMBO J 1985;4:3131-5.
3. Sanchez ER, Toft DO, Schlesinger MJ, Pratt WB. Evidence that the 90-kDa phosphoprotein associated with the untransformed L-cell glucocorticoid receptor is a murine heat shock protein. J Biol Chem 1985;260:12398-401.
4. Bohen SP, Yamamoto KR. Modulation of steroid receptor signal transduction by heat shock proteins. In: Morimoto RI, Tissieres A, Georgopoulos C, editors. The biology of heat shock proteins and molecular chaperones. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1994. p. 313-34.
5. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995;11: 933-9.
6. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 1996;93:8379-83.
7. src with the cellular proteins pp50 and pp90. Curr Top Microbiol Immunol 1986;123: 1-22.
8. Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R, Pratt WB. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 1993;268:21711-6.
9. Wartmann M, Davis RJ. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J Biol Chem 1994; 269:6695-701.
10. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995;270:24585-8.
11. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, et al. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996;271:4974-7.
12. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8.
13. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem 1995;270:16580-7.
14. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801.
15. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998;16:2639-45.
16. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998;3:100-8.
17. Bergerat A, de Massy B, Gadelle D, Varoutas PC, Nicolas A, Forterre P. An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature 1997;386:414-7.
18. (78; Grenert JP, Sullivan WP, Fadden P. Haystead TA, Clark J, Mimnaugh E, et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997;272:23843-50.
19. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75.
20. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50.
21. Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H, et al. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Mol Endocrinol 1999;13:1435-48.
22. Staudenbauer WL, Orr E. DNA gyrase: affinity chromatography on novobiocin-Sepharose and catalytic properties. Nucleic Acids Res 1981;9: 3589-603.
23. Sullivan WP, Toft DO. Mutational analysis of Hsp90 binding to the progesterone receptor. J Biol Chem 1993;268:20373-9.
24. Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res 1991;51:510-3.
25. Neckers LM, Mimnaugh E, Schulte TW. The Hsp90 chaperone family. In: Latchman DS, editor. Handbook of experimental pharmacology. Vol 126. Heidelberg (Germany): Springer-Verlag; 1998. p. 9-42.
26. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992;51:613-9.
27. Johnson JL, Toft DO. Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol 1995;9:670-8.
28. Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Alnemri ES, et al. Nucleotides and two functional states of hsp90. J Biol Chem 1997; 272:8007-12.
29. Lewis RJ, Singh OM, Smith CV, Skarzynski T, Maxwell A, Wonacott AJ, et al. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J 1996;15: 1412-20.
30. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998;79:129-68.
31. Hartson SD, Thulasiraman V, Huang W, Whitesell L, Matts RL. Molybdate inhibits Hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates. Biochemistry 1999;38:3837-49.
32. Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother 1986;30:42-5.
33. Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest 1987;79:1524-8.
34. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.